LONDON and TOKYO, April 18, 2017 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), Kyowa Hakko Kirin Co., Ltd. (Kyowa Hakko Kirin) and Kyowa Kirin International PLC, a wholly owned ...

Ultragenyx, Kyowa Hakko Kirin and Kyowa Kirin International PLC., a wholly owned subsidiary of Kyowa Hakko Kirin, have been collaborating in development and commercialization of burosumab globally ...

Tokyo, Japan, November 16, 2011 --- FUJIFILM Corporation (President and CEO Shigetaka Komori; hereinafter "Fujifilm") and Kyowa Hakko Kirin Co., Ltd. (President and CEO Yuzuru Matsuda; hereinafter ...

Kyowa Kirin is a Japanese pharmaceutical company created by the merger of Kyowa Hakko and Kirin Pharma in 2008. Known for its antibody-based treatments, the current key earnings driver is its ...

Mitsuo Satoh, head of Kyowa Hakko Kirin’s R&D division, said: “As we seek to fulfill our business vision to bring innovative treatments to patients faster, we very much expect that InveniAI ...

Pfizer Inc. (PFE) and Kyowa Hakko Kirin (Tokyo:4151), announced today that they have entered into an agreement to explore the therapeutic potential of the combination of Pfizer's PF-05082566 ...

Kyowa Kirin is a Japanese pharmaceutical company created by the merger of Kyowa Hakko and Kirin Pharma in 2008. Known for its antibody-based treatments, the current key earnings driver is its ...

Kyowa Hakko Kirin has formed another alliance to advance its drug discovery programs, this time focused on fragment-based discovery and featuring NovAliX. The companies will collaborate to develop ...

Japanese brewer Kirin Holdings said on Monday it will bid for control of drugmaker Kyowa Hakko Kogyo in a $2.6 billion deal, with the aim of merging it with its drug unit Kirin Pharma. Kirin said ...

HONG KONG (MarketWatch) -- Brewery group Kirin Holdings Co. said Monday it will seek to take a more than 50% stake in Japanese drug maker Kyowa Hakko Kogyo Co., according to media reports.

Kyowa Hakko Kirin Co. Ltd. and Syndax Pharmaceuticals Inc. have entered into a license agreement for the exclusive rights to develop and commercialize entinostat in Japan and Korea. Entinostat is ...